MX2021015301A - Métodos de cultivo celular y composiciones para la producción de anticuerpos. - Google Patents

Métodos de cultivo celular y composiciones para la producción de anticuerpos.

Info

Publication number
MX2021015301A
MX2021015301A MX2021015301A MX2021015301A MX2021015301A MX 2021015301 A MX2021015301 A MX 2021015301A MX 2021015301 A MX2021015301 A MX 2021015301A MX 2021015301 A MX2021015301 A MX 2021015301A MX 2021015301 A MX2021015301 A MX 2021015301A
Authority
MX
Mexico
Prior art keywords
compositions
cell culture
culture methods
antibody production
antibody
Prior art date
Application number
MX2021015301A
Other languages
English (en)
Inventor
Yogender Kumar Gowtham
Sokha Susan Lay
Scarfo Edmund G
Nandita Vishwanathan
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2021015301A publication Critical patent/MX2021015301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención proporciona métodos de cultivo celular para producir un anticuerpo anti-¿4ß7, por ejemplo, vedolizumab, así como composiciones de este.
MX2021015301A 2019-06-10 2020-06-10 Métodos de cultivo celular y composiciones para la producción de anticuerpos. MX2021015301A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859596P 2019-06-10 2019-06-10
US201962859563P 2019-06-10 2019-06-10
PCT/US2020/037080 WO2020252082A1 (en) 2019-06-10 2020-06-10 Cell culture methods and compositions for antibody production

Publications (1)

Publication Number Publication Date
MX2021015301A true MX2021015301A (es) 2022-02-03

Family

ID=73780813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015301A MX2021015301A (es) 2019-06-10 2020-06-10 Métodos de cultivo celular y composiciones para la producción de anticuerpos.

Country Status (14)

Country Link
US (1) US20220267448A1 (es)
EP (1) EP3980068A4 (es)
JP (1) JP2022536658A (es)
KR (1) KR20220019725A (es)
CN (4) CN117925709A (es)
AU (1) AU2020291920A1 (es)
BR (1) BR112021024852A2 (es)
CA (1) CA3143246A1 (es)
IL (1) IL288819A (es)
MA (1) MA56130A (es)
MX (1) MX2021015301A (es)
PL (1) PL439808A1 (es)
TW (1) TW202112819A (es)
WO (1) WO2020252082A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023021532A1 (en) * 2021-08-20 2023-02-23 Dr. Reddy’S Laboratories Limited A process to produce a pharmaceutical composition
WO2024096506A1 (ko) * 2022-10-31 2024-05-10 삼성바이오에피스 주식회사 고농도 액체 배지 제조 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0953041A4 (en) * 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
CA2629147A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
US8911964B2 (en) * 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2008232902B2 (en) * 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
ES2560470T3 (es) * 2011-04-29 2016-02-19 Biocon Research Limited Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
HU231463B1 (hu) * 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
KR20210016479A (ko) * 2015-12-04 2021-02-15 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법

Also Published As

Publication number Publication date
CA3143246A1 (en) 2020-12-17
KR20220019725A (ko) 2022-02-17
WO2020252082A1 (en) 2020-12-17
PL439808A1 (pl) 2022-12-05
CN117925709A (zh) 2024-04-26
BR112021024852A2 (pt) 2022-02-15
MA56130A (fr) 2022-04-13
EP3980068A1 (en) 2022-04-13
CN114206383A (zh) 2022-03-18
IL288819A (en) 2022-02-01
CN117925710A (zh) 2024-04-26
US20220267448A1 (en) 2022-08-25
CN117925711A (zh) 2024-04-26
JP2022536658A (ja) 2022-08-18
TW202112819A (zh) 2021-04-01
AU2020291920A1 (en) 2022-02-03
EP3980068A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
EP4038178A4 (en) NUTRIENT COMPOSITIONS AND METHODS, KITS AND CELLULAR COMPOSITIONS FOR THE PRODUCTION THEREOF
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
WO2018109174A3 (en) Il-11 antibodies
PH12019502283A1 (en) Anti-lag3 antibodies
WO2018109170A3 (en) Il-11ra antibodies
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
MX2021010827A (es) Materiales funcionales de origen vegetal.
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
MX2021008621A (es) Anticuerpos de inmunoglobulina a y metodos de produccion y uso.
MX2022001641A (es) Composiciones fermentadas y procedimientos de preparacion de las mismas.
MX2021015301A (es) Métodos de cultivo celular y composiciones para la producción de anticuerpos.
MX2022001428A (es) Metodos y composiciones para cultivar bacterias dependientes de hemoglobina.
WO2020128870A3 (en) Methods of producing heterodimeric antibodies
MX2022001694A (es) Metodos y composiciones para mejorar el rendimiento de soya.
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases